Skip to main content

Summary

for people ages 18–75 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of ABT-494.

Official Title

A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT-494 in Subjects With Crohn's Disease

Keywords

Crohn's Disease (CD) Crohn's Disease Efficacy Safety Tolerability ABT-494 Crohn Disease

Eligibility

You can join if…

Open to people ages 18–75

  • Participant must have completed Study M13-740 through Week 52.
  • If female, participant must be postmenopausal, surgically sterile or on using a birth control method.

You CAN'T join if...

  • For any reason participant is considered by the investigator to be an unsuitable candidate
  • Female participant with a positive pregnancy test at Baseline or who is considering becoming pregnant during the study.
  • Participant is not in compliance with prior and concomitant medication requirements and procedures throughout Study M13-740.

Locations

  • Univ California, San Francisco
    San Francisco, California, 94143-2204, United States
  • UCSD
    La Jolla, California, 92037, United States
  • Aspen Clinical Research
    Orem, Utah, 84058, United States
  • University of Washington
    Seattle, Washington, 98109, United States
  • Univ British Columbia
    Vancouver, British Columbia, V5Z 4E8, Canada
  • (GIRI) GI Research Institute
    Vancouver, British Columbia, V6Z 2K5, Canada
  • Zeidler Ledcor Centre
    Edmonton, Alberta, T6G 2X8, Canada
  • Texas Digestive Disease Consul
    Southlake, Texas, 76092, United States
  • Cotton-O'Neil Clinical Res Ctr
    Topeka, Kansas, 66606, United States
  • Options Health Research, LLC
    Tulsa, Oklahoma, 74104, United States
  • Kansas City Research Institute
    Kansas City, Missouri, 64131, United States
  • Mayo Clinic
    Rochester, Minnesota, 55905-0001, United States
  • Washington University-School of Medicine
    Saint Louis, Missouri, 63110, United States
  • WI Center for Advanced Res
    Madison, Wisconsin, 53215, United States
  • University of Louisville
    Louisville, Kentucky, 40202, United States
  • University of Cincinnati
    Cincinnati, Ohio, 45267-2827, United States
  • Center for Digestive Health
    Troy, Michigan, 48098-6363, United States
  • Gastrointestinal Specialists
    Marietta, Georgia, 30060, United States
  • Gastro Assoc of Central GA
    Macon, Georgia, 31201, United States
  • London Health Sciences Centre
    London, Ontario, N6A 5A5, Canada
  • Medicor Research Inc.
    Sudbury, Ontario, P3A 1W8, Canada
  • Toronto Digestive Disease Asso
    Vaughan, Ontario, L4L 4Y7, Canada
  • University of Florida
    Gainesville, Florida, 32610, United States
  • Nature Coast Clinical Research
    Inverness, Florida, 34452, United States
  • Univ NC Chapel Hill
    Chapel Hill, North Carolina, 27514-4220, United States
  • University of Virginia
    Charlottesville, Virginia, 22908, United States
  • Med Univ of South Carolina
    Charleston, South Carolina, 29425, United States
  • Charm City Research Group
    Towson, Maryland, 21204, United States
  • Ridgely Oaks Professional Center
    Annapolis, Maryland, 21401, United States
  • The Ctr for Gastro Disorders
    Hollywood, Florida, 33021, United States
  • Columbia Univ Medical Center
    New York, New York, 10032-3725, United States
  • NYU Langone Long Island CRA
    Great Neck, New York, 11021, United States
  • McGill Univ HC
    Montreal, Quebec, H3G 1A4, Canada
  • Lovisenberg Diakonale Sykehus
    Oslo, 0440, Norway
  • Manchester Royal Infirmary, Ma
    Manchester, M13 9WL, United Kingdom
  • John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
  • Aarhus University Hospital
    Aarhus C, Midtjylland, 8000, Denmark
  • Hvidovre Hospital
    Hvidovre, 2650, Denmark
  • Academisch Medisch Centrum
    Amsterdam, Noord-Holland, 1105 AZ, Netherlands
  • UMC Utrecht
    Utrecht, 3584 CX, Netherlands
  • CHU de Liege
    Liège, Liege, 4000, Belgium
  • Univ Hosp Schleswig-Holstein
    Kiel, Schleswig-Holstein, 24105, Germany
  • DRK-Kliniken Westend
    Berlin, 14050, Germany
  • MVZ Portal 10
    Munster, 48155, Germany
  • CHRU Lille - Hôpital Claude Huriez
    Lille CEDEX, Hauts-de-France, 59045, France
  • CHU NANCY - Hôpital Brabois Adultes
    Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, 54511, France
  • CHU Amiens Picardie
    Amiens CEDEX 1, Somme, 80054, France
  • Hospital Arquitecto Marcide
    Ferrol, 15405, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • C.M. Szpital Swietej Rodziny
    Łódź, Lodzkie, 90-302, Poland
  • Centralny Szpital Kliniczny MSWiA w Warszawie
    Warszawa, Mazowieckie, 02-507, Poland
  • Hepato-Gastro HK, s.r.o.
    Hradec Kralove, 500 12, Czechia
  • KM Management s.r.o, Nitra, SK
    Nitra, 949 01, Slovakia
  • Gastro I.S.R.O.
    Presov, 08001, Slovakia
  • Università di Catanzaro "Magna Graecia"
    Catanzaro, Calabria, 88100, Italy
  • A.O.U. Policlinico S.Orsola-Malpighi
    Bologna, Emilia-Romagna, 40138, Italy
  • Cabinet Particular Algomed SRL
    Timisoara, 300002, Romania
  • Rabin Medical Center
    Petakh Tikva, Tel-Aviv, 4941492, Israel
  • Assaf Harofeh Medical Center
    Be'er Ya'akov, 70300, Israel
  • Sheba Medical Center
    Ramat Gan, 5262100, Israel

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
ID
NCT02782663
Phase
Phase 2
Lead Scientist
Jonathan Terdiman
Study Type
Interventional
Last Updated
April 16, 2018